MIGHTYZOL™

Linezolid is the first-in-class oxazolidinone antibiotic, with a mechanism of action entirely distinct from all other antibiotic classes. It inhibits bacterial protein synthesis at the very initiation step — specifically, it binds to the 23S ribosomal RNA of the 50S subunit, preventing the formation of the functional 70S initiation complex (the ribosomal assembly required to begin translating mRNA into protein). Without a functional initiation complex, protein synthesis cannot begin, and the bacterium cannot replicate or produce essential virulence factors.

This is a uniquely early point of inhibition — other ribosomal antibiotics (macrolides, aminoglycosides, tetracyclines) target later stages of protein synthesis. By acting at initiation rather than elongation or translocation, linezolid has no cross-resistance with these antibiotic classes. A bacterium resistant to macrolides, aminoglycosides, or tetracyclines remains fully susceptible to linezolid.

Critically, linezolid is active against gram-positive organisms that are resistant to essentially all other antibiotic classes:
— Methicillin-resistant Staphylococcus aureus (MRSA)
— Vancomycin-resistant Enterococci (VRE)
— Penicillin-resistant Streptococcus pneumoniae
— Multi-drug-resistant tuberculosis (MDR-TB) — as part of WHO-recommended regimens

At 100mg per 5mL, MIGHTYZOL™ Dry Syrup provides the paediatric linezolid formulation for patients who cannot swallow tablets, maintaining the full spectrum of linezolid's unique activity against resistant gram-positive organisms in a palatable liquid format. Oral bioavailability of linezolid is approximately 100% — identical to the intravenous formulation — enabling complete step-down from IV to oral therapy without any loss of drug exposure.

MIGHTYZOL™ Dry Syrup is a reserve antibiotic indicated for serious or complicated gram-positive infections caused by multi-drug-resistant organisms where first-line and second-line antibiotics have failed or are not appropriate.

MRSA Infections: Skin and soft tissue infections, pneumonia, bacteraemia, and osteomyelitis caused by methicillin-resistant Staphylococcus aureus in paediatric patients. Linezolid is a guideline-endorsed alternative to vancomycin for MRSA infections in patients who cannot tolerate glycopeptides.

VRE Infections: Complicated urinary tract infections, bacteraemia, and abdominal infections caused by vancomycin-resistant Enterococcus faecium — an organism for which linezolid is one of the few consistently effective agents.

Drug-Resistant Pneumonia: Community-acquired pneumonia caused by penicillin-resistant S. pneumoniae or MRSA in children requiring step-down from parenteral therapy. Linezolid achieves excellent lung parenchyma concentrations.

MDR-TB: As part of WHO-recommended longer regimens for multi-drug-resistant tuberculosis in paediatric patients — a specific and guideline-endorsed indication.

Complicated Skin Infections: Diabetic foot infections, necrotising fasciitis, and deep-space infections with confirmed or suspected MRSA involvement.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.